Chronic Migraine: How Eptinezumab Affects Headache Impact Test-6 Scores

In this video, Richard Lipton, MD, discusses the results of the PROMISE-2 trial, including the observed reductions in Headache Impact Test-6 (HIT-6) total and item scores among patients with chronic migraine who were treated with eptinezumab. Read the transcript here. These findings were presented at the American Academy of Neurology 2020 Virtual Science Highlights.

For more videos like this, visit Neurology Consultant.

Richard Lipton, MD, is a professor of neurology and epidemiology at the Albert Einstein College of Medicine, and director of the Montefiore Headache Center in Bronx, New York.

Reference:

• Wirth R, McGinley J, Houts C, Hirman J, Cady R, Lipton R. Eptinezumab demonstrated early and sustained reductions in HIT-6 total and item scores over time in patients with chronic migraine in the PROMISE-2 trial. Paper presented at: American Academy of Neurology 2020 Virtual Science Highlights; May 14, 2020; Virtual. https://cslide-us.ctimeetingtech.com/aan2020/attendee/eposter/poster/2665?q=eptinezumab